IGC (IGC Pharma) OCF Margin %: -385.80% (As of Mar. 2026)

What is IGC Pharma OCF Margin %?

IGC Pharma IGC +1.79% 29 OCF Margin % is -385.80% as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, IGC Pharma ranks worse than 73.41% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. IGC Pharma's Cash Flow from Operations for the three months ended in Mar. 2026 was $-1.22 Mil. IGC Pharma's Revenue for the three months ended in Mar. 2026 was $0.32 Mil. Therefore, IGC Pharma's OCF Margin % for the quarter that ended in Mar. 2026 was -385.80%.

As of today, IGC Pharma's current OCF Yield % is -22.27%.

The historical rank and industry rank for IGC Pharma's OCF Margin % or its related term are showing as below:

IGC' s OCF Margin % Range Over the Past 10 Years
Min: -1879.6 Med: -279.83 Max: -2.48
Current: -501.1

During the past 13 years, the highest OCF Margin % of IGC Pharma was -2.48%. The lowest was -1879.60%. And the median was -279.83%.

IGC's OCF Margin % is ranked worse than
73.41% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs IGC: -501.10

IGC Pharma OCF Margin % Related Terms

IGC Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for IGC Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma OCF Margin % Chart

IGC Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

OCF Margin %

Get a 7-Day Free Trial

-1,202.67

-1,879.60

-773.55

-386.54

-319.83

IGC Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															0.00	-428.96	-1,094.24	-349.43	-385.80

IGC vs CRVO, NEUP, CELU: OCF Margin % Comparison

For the Biotechnology subindustry, IGC Pharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's OCF Margin % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's OCF Margin % falls into.

Save Embed

29GF Score

IGC Pharma Inc IGC

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

IGC Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

IGC Pharma's OCF Margin for the fiscal year that ended in Mar. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Mar. 2025 )	/	Revenue (A: Mar. 2025 )
	=	-4.065	/	1.271
	=	-319.83 %

IGC Pharma's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-1.223	/	0.317
	=	-385.80 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of -385.80% mean?

IGC Pharma (IGC) has a OCF Margin % of -385.80% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on IGC Pharma and its competitors. According to the industry distribution chart, IGC Pharma ranks #704 out of 959 companies in the Biotechnology industry, placing it in the top 73.4%.

Is IGC Pharma's OCF Margin % too high?

IGC Pharma's current OCF Margin % is -385.80%. Based on the distribution chart, IGC Pharma ranks #704 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does IGC Pharma's OCF Margin % compare to CRVO and NEUP?

According to the Biotechnology industry distribution chart, IGC Pharma ranks #704 out of 959 companies for OCF Margin %. This places IGC Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on IGC Pharma and its competitors. IGC Pharma's current OCF Margin % is -385.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is IGC Pharma stock overvalued right now?

Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 11.1% above its estimated fair value. The current OCF Margin % is -385.80%. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For IGC Pharma (IGC), the current OCF Margin % is -385.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.27 is trading 11.1% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

OCF Margin %: -385.80%
GF Value™: $0.24 vs. price of $0.27 (11.1% above fair value)
GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies CRVO NEUP CELU DYAI SNSE SNTI NRSN LSTA KYNB SER VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges IGS1:Germany

Address 10224 Falls Road, Potomac, MD, USA, 20854

Website https://www.igcinc.us

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

29GF Score

Get the complete analysis for IGC

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27

Price

$0.24

GF Value

View IGC Analysis

See OCF Margin % data for all stocks →